Using Sacituzumab Govitecan and Other ADCs in Urothelial Cancers
Arlene O. Siefker-Radtke, MD, discusses the data seen with sacituzumab govitecan, an antibody-drug conjugate that targets TROP-2, which is expressed frequently in urothelial cancer cells.
Arlene O. Siefker-Radtke, MD, professor, department of genitourinary medical oncology, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the data seen with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) that targets TROP-2, which is expressed frequently in urothelial cancer cells.
Response rates were around 30% with this agent, but it was associated with toxicites, says Siefker-Radtke. However, toxicities are common with other ADCs, such as enfortumab vedotin, which has a higher rate of neutropenia and neutropenic fevers.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
